Literature DB >> 9212044

Cardiovascular defects among the progeny of mouse phenylketonuria females.

J D McDonald1, C A Dyer, L Gailis, M L Kirby.   

Abstract

In a genetic mouse model of human phenylketonuria we have examined the offspring of hyperphenylalaninemic mothers for the presence of cardiovascular defects, an important feature of the pathology of the human maternal phenylketonuria syndrome. Beginning at 14.5 d after conception (75% through gestation), a variety of cardiovascular defects became apparent among the progeny of the hyperphenylalaninemic females. These defects ranged from mild to serious and correlated with the maternal but not the fetal Pah genotype. Nearly all of the defects were vascular, however, whereas the most reported in humans so far have been cardiac. The predisposing biochemical condition in this mouse disease model seems to be the same as in the human disease; elevated maternal blood phenylalanine levels concentrated across the placental barrier to produce a teratogenic developmental environment. This model for congenital cardiovascular defects should enhance two related areas of research. 1) It should allow a more thorough investigation of the relationship between maternal diet and maternal phenylketonuria birth defects, and 2) it should provide an experimental tool to gain insight into the normal process of cardiovascular development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212044     DOI: 10.1203/00006450-199707000-00016

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

Review 1.  State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.

Authors:  Hiu Man Grisch-Chan; Gerald Schwank; Cary O Harding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2019-09-09       Impact factor: 5.695

Review 2.  Progress toward cell-directed therapy for phenylketonuria.

Authors:  Co Harding
Journal:  Clin Genet       Date:  2008-05-21       Impact factor: 4.438

3.  Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Ming Ying; Aurora Martinez; Sydney Weber; Jacob Raber; Cary O Harding
Journal:  Mol Genet Metab       Date:  2017-10-19       Impact factor: 4.797

4.  Cardiac teratogenicity in mouse maternal phenylketonuria: defining phenotype parameters and genetic background influences.

Authors:  Nikki J Seagraves; Kim L McBride
Journal:  Mol Genet Metab       Date:  2012-08-08       Impact factor: 4.797

5.  High levels of orexin A in the brain of the mouse model for phenylketonuria: possible role of orexin A in hyperactivity seen in children with PKU.

Authors:  Sankar Surendran; Gerald A Campbell; Stephen K Tyring; Kimberlee Matalon; J David McDonald; Reuben Matalon
Journal:  Neurochem Res       Date:  2003-12       Impact factor: 3.996

6.  Modeling the cognitive effects of diet discontinuation in adults with phenylketonuria (PKU) using pegvaliase therapy in PAH-deficient mice.

Authors:  Shelley R Winn; Sandra Dudley; Tanja Scherer; Nicole Rimann; Beat Thöny; Sydney Boutros; Destine Krenik; Jacob Raber; Cary O Harding
Journal:  Mol Genet Metab       Date:  2022-03-21       Impact factor: 4.204

7.  Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU.

Authors:  Katherine E Durrer; Michael S Allen; Ione Hunt von Herbing
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

8.  AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria.

Authors:  Daelyn Y Richards; Shelley R Winn; Sandra Dudley; Sean Nygaard; Taylor L Mighell; Markus Grompe; Cary O Harding
Journal:  Mol Ther Methods Clin Dev       Date:  2019-12-24       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.